Use of a highly-sensitive cardiac troponin I assay in a screening population for hypertrophic cardiomyopathy: A case-referent study

BMC Cardiovascular Disorders

Volumn 13, Issue , 2013, Pages

  McGorrian, Catherine M ^a,b   Lyster, Sarah ^b   Roy, Andrew ^a   Tarrant, Heloise ^a   Codd, Mary ^b   Doran, Peter ^a   Fitzgibbon, Maria ^a   Galvin, Joseph ^a,c   Mahon, Niall G ^a  

^a MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

^c Royal College of Surgeons in Ireland   (Ireland)

Author keywords

Biomarkers; High risk screening; Highly sensitive assays; Hypertrophic cardiomyopathy; Troponin I

Indexed keywords

TROPONIN I;

ADULT; ARTICLE; ASSAY; BLOOD SAMPLING; CASE CONTROL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC KIT; ECHOCARDIOGRAPHY; FEMALE; HEART MUSCLE; HIGH RISK POPULATION; HIGHLY SENSITIVE CARDIAC TROPONIN I ASSAY; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; MUSCLE MASS; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN LOCALIZATION; RECEIVER OPERATING CHARACTERISTIC; RELATIVE; RISK ASSESSMENT; SCREENING; SENSITIVITY AND SPECIFICITY; VENOUS BLOOD;

ADULT; BIOLOGICAL MARKERS; CALIBRATION; CARDIOMYOPATHY, HYPERTROPHIC; CASE-CONTROL STUDIES; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; POPULATION SURVEILLANCE; PROSPECTIVE STUDIES; SINGLE-BLIND METHOD; TROPONIN T; YOUNG ADULT;

EID: 84883632768     PISSN: None     EISSN: 14712261     Source Type: Journal    
DOI: 10.1186/1471-2261-13-70     Document Type: Article

References (27)

1. Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn HJ, Seidman CE, Shah PM, Spencer WH, Spirito P, Ten Cate FJ, Wigle ED. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. J Am Coll Cardiol 2003, 42:1687-1713. 10.1016/S0735-1097(03)00941-0, 14607462.
2. Maron BJ. Hypertrophic cardiomyopathy:a systematic review. JAMA 2002, 287:1308-1320. 10.1001/jama.287.10.1308, 11886323.
3. Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, Naidu SS, Nishimura RA, Ommen SR, Rakowski H, Seidman CE, Towbin JA, Udelson JE, Yancy CW. ACCF/AHA guideline for the diagnosis and management of hypertrophic cardiomyopathy. J Am Coll Cardiol 2011, 58:e212-e260. 10.1016/j.jacc.2011.06.011, 22075469.
4. Keren A, Syrris P, McKenna WJ. Hypertrophic cardiomyopathy: the genetic determinants of clinical disease expression. Nat Rev Cardiol 2008, 5:158-168.
5. Basavarajaiah S, Wilson M, Whyte G, Shah A, McKenna W, Sharma S. Prevalence of hypertrophic cardiomyopathy in highly trained athletes: relevance to pre-participation screening. J Am Coll Cardiol 2008, 51:1033-1039. 10.1016/j.jacc.2007.10.055, 18325444.
6. Desai MY, Ommen SR, McKenna WJ, Lever HM, Elliott PM. Imaging phenotype versus genotype in hypertrophic cardiomyopathy. Circ Cardiovasc Imaging 2011, 4:156-168. 10.1161/CIRCIMAGING.110.957936, 21406662.
7. Taniguchi R, Sato Y, Nishio Y, Kimura T, Kita T. Measurements of baseline and follow-up concentrations of cardiac troponin-T and brain natriuretic peptide in patients with heart failure from various etiologies. Heart Vessels 2006, 21:344-349. 10.1007/s00380-006-0909-1, 17143708.
8. Kubo T, Kitaoka H, Okawa M, Yamanaka S, Hirota T, Hoshikawa E, Hayato K, Yamasaki N, Matsumura Y, Yasuda N, Sugiura T, Doi YL. Serum cardiac troponin I is related to increased left ventricular wall thickness, left ventricular dysfunction, and male gender in hypertrophic cardiomyopathy. Clin Cardiol 2010, 33:E1-E7.
9. Moreno V, Hernandez-Romero D, Vilchez JA, Garcia-Honrubia A, Cambronero F, Casas T, Gonzalez J, Martinez P, Climent V, de la Morena G, Valdes M, Maron F. Serum levels of high-sensitivity Troponin T: A novel marker for cardiac remodeling in hypertrophic cardiomyopathy. J Card Fail 2010, 16:950-956. 10.1016/j.cardfail.2010.07.245, 21111984.
10. Apple FS, Collinson PO. Analytical characteristics of high-sensitivity cardiac troponin assays. Clin Chem 2012, 58:54-61. 10.1373/clinchem.2011.165795, 21965555.
11. Corrado D, Basso C, Schiavon M, Pelliccia A, Thiene G. Pre-participation screening of young competitive athletes fro prevention of sudden cardiac death. J Am Coll Cardiol 2008, 51:1981-1989.
12. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ, Chamber Quantification Writing Group Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005, 18:1440-1463. 10.1016/j.echo.2005.10.005, 16376782, Chamber Quantification Writing Group.
13. Gottdiener JS, Bednarz J, Devereux R, Gardin J, Klein A, Manning WJ, Morehead A, Kitzman D, Oh J, Quinones M, Schiller NB, Stein JH, Weissman NJ. American Society of Echocardiography recommendations for use of echocardiography in clinical trials. J Am Soc Echocardiogr 2004, 17:1086-1119.
14. Spirito P, Bellone P, Harris KM, Bernabò P, Bruzzi P, Maron BJ. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med 2000, 342:1778-1785. 10.1056/NEJM200006153422403, 10853000.
15. Forissier JF, Charon P, du Tezenas MS, Hagege A, Isnard R, Carrier L, Richard P, Desnons M, Bouhour JB, Schwartz K, Komajda M, Dubourg O. Diagnostic accuracy of a 2D left ventricle hypertrophy score for familial hypertrophic cardiomyopathy. Eur Heart J 2005, 26:1882-1886. 10.1093/eurheartj/ehi276, 15860513.
16. Gandjbakhch E, Gackowski A, du Tezenas MS, Isnard R, Hamroun A, Richard P, Komajda M, Charron P. Early identification of mutation carriers in familial hypertrophic cardiomyopathy by combined echocardiography and tissue doppler imaging. Eur Heart J 2010, 31:1599-1607. 10.1093/eurheartj/ehq101, 20439259.
17. Hlatky MA, Greenland P, Arnett DK, Ballantyne CM, Criqu MH, Elkind MSV, Go AS, Harrell FE, Hong Y, Howard BV, Howard VJ, Hsue PY, Kramer CM, McConnell JP, Normand SL, O'Donnell CJ, Smith SC, Wilson PWF. Criteria for evaluation of novel markers of cardiovascular risk. A scientific statement from the American Heart Association. Circulation 2009, 119:2408-2416. 10.1161/CIRCULATIONAHA.109.192278, 2956982, 19364974.
18. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982, 143:29-36.
19. Pencina MJ. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008, 27:157-172. 10.1002/sim.2929, 17569110.
20. Leistner DM, Klotsche J, Pieper L, Stalla GK, Lehnert H, Silber S, Marz W, Wittchen HU, Zeiher AM. Circulating Troponin as measured by a sensitive assay for cardiovascular risk assessment in primary prevention. Clin Chem 2012, 58:200-208. 10.1373/clinchem.2011.174292, 22156668.
21. Saunders JT, Nambi V, de Lemos JA, Chambless LE, Virani SS, Boerwinkle E, Hoogeveen RC, Liu X, Astor BC, Mosley TH, Folsom AR, Heiss G, Coresh J, Ballantyne CM. Cardiac Troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the atherosclerosis risk in communities study. Circulation 2011, 123:1367-1376. 10.1161/CIRCULATIONAHA.110.005264, 3072024, 21422391.
22. Cambronero F, Marin F, Roldan V, Hernandez-Romero D, Valdes M, Lip GYH. Biomarkers of pathophysiology in hypertrophic cardiomyopathy: implications for clinical management and prognosis. Eur Heart J 2009, 30:139-151.
23. Sato Y, Taniguchi R, Nagai K, Makiyama T, Okada H, Yamada T, Matsumori A, Takatsu Y. Measurements of cardiac troponin T in patients with hypertrophic cardiomyopathy. Heart 2003, 89:659-660. 10.1136/heart.89.6.659, 1767695, 12748227.
24. Tanislav C, Feustel A, Franzen W, Wusten O, Schneider C, Reichenberger F, Rolfs A, Siewke N. Persistent increase in cardiac troponin I in Fabry disease: a case report. BMC Cardiovasc Dis 2011, 11:6.
25. Kubo T, Kitaoka H, Okawa M, Yamanaka S, Hirota T, Baba Y, Hayato K, Yamasaki N, Matsumura Y, Yasuda N, Sugiura T, Doi YL. Combined measurements of cardiac troponin I and brain natriuretic peptide are useful for predicting adverse outcomes in hypertrophic cardiomyopathy. Circ J 2011, 75:919-926. 10.1253/circj.CJ-10-0782, 21304210.
26. Wilson MG, Basavarajaiah S, Whyte GP, Cox S, Loosemore M, Sharma S. Efficacy of personal symptom and family history questionnaires when screening for inherited cardiac pathologies: the role of electrocardiography. Br J Sports Med 2008, 42:207-211. 10.1136/bjsm.2007.039420, 17717062.
27. Maron BJ. Distinguishing hypertrophic cardiomyopathy from athlete's heart physiological remodelling: clinical significance, diagnostic strategies and implications for preparticipation screening. Br J Sports Med 2009, 43:649-656. 10.1136/bjsm.2008.054726, 19734498.